Harmony Biosciences Holdings, Inc.HRMY

Where HRMY's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$39.38+0.17 (+0.43%)Previous close
NASDAQHealthcare

HRMY Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
HRMY Net Debt / EBITDA historyHRMY Net Debt / EBITDA from Sep 2023 to Jun 2026: low -2.04, high -0.5, latest -1.43.-2.16-1.72-1.27-0.82-0.37Sep 23Mar 24Sep 24Jun 25Dec 25Jun 26med -1.31

HRMY Net Debt / EBITDA by year

Yearly range of HRMY’s net debt / ebitda from 2019 to 2026. Over the full period it ranged from -2.0 to 1.6, averaging -0.7.

HRMY Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
2026-1.6-1.5-1.4-1.4
2025-2.0-1.6-1.3-2.0
2024-1.2-0.8-0.6-1.2
2023-0.7-0.6-0.5-0.5
2022-0.7-0.5-0.4-0.4
2021-0.70.21.0-0.7
2020-2.0-0.81.6-1.3
2019-0.5-0.5-0.5-0.5

Get notified when HRMY Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.